A Phase 1b, Randomised, Controlled Age De-escalation, Dose-finding Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Full-length MSP1/GLA-SE (SUM-101) Malaria Vaccine in Healthy Young Children, and Infants in Burkina Faso
Latest Information Update: 16 Sep 2026
At a glance
- Drugs SUM-101 (Primary) ; Rabies vaccine
- Indications Falciparum malaria; Malaria
- Focus Adverse reactions
- Acronyms SUM-101
Most Recent Events
- 11 Sep 2026 Status changed from active, no longer recruiting to completed.
- 21 Nov 2025 Status changed from recruiting to active, no longer recruiting.
- 11 Aug 2025 Planned primary completion date changed from 31 Dec 2025 to 31 Jan 2026.